MO01.38 Registrational Dataset from the Phase 1/2 ARROW Trial of Pralsetinib (BLU-667) in Patients with Advanced RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC)
Year: 2021
Type: conference-abstract
Source: Journal of Thoracic Oncology
Institutions: Massachusetts General Hospital, University of Milan, European Institute of Oncology, Seoul National University Hospital, Asan Medical Center, University of Ulsan, Université Paris-Sud, Institut Gustave Roussy, University of Washington, University of Washington Medical Center, University of Colorado Cancer Center, Centre Léon Bérard, University of Miami, Sylvester Comprehensive Cancer Center, National Cancer Centre Singapore, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Universitario 12 De Octubre, Yonsei University, Yonsei Cancer Hospital, Henry Ford Health, University Hospital Heidelberg, Georgetown University, Blueprint Medicines (United States), The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3119736867